A protein linked to worse outcomes with a glioblastoma drug
Original title: Annexin A2 associated with bevacizumab resistance and infiltrative escape in glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors looked at tumor samples from patients, but nothing new was tested as a treatment.
The short version
Tumors with a lot of a protein called ANXA2 did worse on a drug called bevacizumab.
What was studied. Doctors looked at 66 tissue samples from 33 people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary. They measured a protein called ANXA2 in the tumor tissue. The group included 15 people who had not taken bevacizumab and 18 who had.
What they found. High ANXA2 levels went with shorter time before the tumor grew again. High levels also went with shorter survival. Among people who got bevacizumab, those with low ANXA2 lived longer than those with high ANXA2. The protein was strongest at the outer edge of the tumor, in blood vessels and in areas low on oxygen.
What this means, and what it doesn't
What it could mean: ANXA2 may one day help doctors guess who will get lasting help from bevacizumab. It may also help explain why the drug often stops working after a while. For now it is a clue about the tumor, not a new treatment.
What it doesn't mean: This does not mean there is a new drug or a new test you can get. The team studied tumor tissue that was already removed during surgery. They did not try treating anyone based on ANXA2. The study authors say the idea still needs more testing. This is early science, far from everyday care, and it is not a cure.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.